CY1122551T1 - Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων - Google Patents
Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτωνInfo
- Publication number
- CY1122551T1 CY1122551T1 CY20191100155T CY191100155T CY1122551T1 CY 1122551 T1 CY1122551 T1 CY 1122551T1 CY 20191100155 T CY20191100155 T CY 20191100155T CY 191100155 T CY191100155 T CY 191100155T CY 1122551 T1 CY1122551 T1 CY 1122551T1
- Authority
- CY
- Cyprus
- Prior art keywords
- obese
- morbidly
- patient
- methods
- compounds
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 208000008589 Obesity Diseases 0.000 title 1
- 235000020824 obesity Nutrition 0.000 title 1
- YCGBUPXEBUFYFV-UHFFFAOYSA-N withaferin A Natural products CC(C1CC(=C(CO)C(=O)O1)C)C2CCC3C4CC5OC56C(O)C=CC(O)C6(C)C4CCC23C YCGBUPXEBUFYFV-UHFFFAOYSA-N 0.000 abstract 2
- DBRXOUCRJQVYJQ-CKNDUULBSA-N withaferin A Chemical compound C([C@@H]1[C@H]([C@@H]2[C@]3(CC[C@@H]4[C@@]5(C)C(=O)C=C[C@H](O)[C@@]65O[C@@H]6C[C@H]4[C@@H]3CC2)C)C)C(C)=C(CO)C(=O)O1 DBRXOUCRJQVYJQ-CKNDUULBSA-N 0.000 abstract 2
- 210000000577 adipose tissue Anatomy 0.000 abstract 1
- 239000000883 anti-obesity agent Substances 0.000 abstract 1
- 230000037406 food intake Effects 0.000 abstract 1
- 235000012631 food intake Nutrition 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000004580 weight loss Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/2264—Obesity-gene products, e.g. leptin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Endocrinology (AREA)
- Genetics & Genomics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361908998P | 2013-11-26 | 2013-11-26 | |
| PCT/US2014/067393 WO2015081093A1 (en) | 2013-11-26 | 2014-11-25 | Compounds for the treatment of obesity and methods of use thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122551T1 true CY1122551T1 (el) | 2021-01-27 |
Family
ID=52134396
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191100155T CY1122551T1 (el) | 2013-11-26 | 2019-02-05 | Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US20160375039A1 (enExample) |
| EP (1) | EP3074033B1 (enExample) |
| JP (2) | JP6672157B2 (enExample) |
| AU (2) | AU2014354831B2 (enExample) |
| CA (1) | CA2931826C (enExample) |
| CY (1) | CY1122551T1 (enExample) |
| DK (1) | DK3074033T3 (enExample) |
| ES (1) | ES2709976T3 (enExample) |
| HR (1) | HRP20190219T1 (enExample) |
| HU (1) | HUE042196T2 (enExample) |
| LT (1) | LT3074033T (enExample) |
| PL (1) | PL3074033T3 (enExample) |
| PT (1) | PT3074033T (enExample) |
| RS (1) | RS58422B1 (enExample) |
| SI (1) | SI3074033T1 (enExample) |
| SM (1) | SMT201900064T1 (enExample) |
| TR (1) | TR201901299T4 (enExample) |
| WO (1) | WO2015081093A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015153933A1 (en) * | 2014-04-03 | 2015-10-08 | The Children's Medical Center Corporation | Hsp90 inhibitors for the treatment of obesity and methods of use thereof |
| CN106008657B (zh) * | 2016-05-20 | 2017-11-21 | 天津中医药大学 | 苦蘵苦素i及提取方法及用途 |
| IT201800005336A1 (it) * | 2018-05-14 | 2019-11-14 | Composizioni per uso nel trattamento dell’obesità | |
| WO2021072139A1 (en) * | 2019-10-11 | 2021-04-15 | Massachusetts Institute Of Technology | Formulations for gastrointestinal delivery of oligonucleotides |
| CN113599502A (zh) * | 2021-07-22 | 2021-11-05 | 廖儒佳 | 一种醉茄素a和瘦素的组合物及其在制备预防和或治疗出血性脑卒中药物中的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ZA791659B (en) | 1978-04-17 | 1980-04-30 | Ici Ltd | Process and apparatus for spraying liquid |
| GB8504253D0 (en) | 1985-02-19 | 1985-03-20 | Ici Plc | Electrostatic spraying apparatus |
| US4938763B1 (en) | 1988-10-03 | 1995-07-04 | Atrix Lab Inc | Biodegradable in-situ forming implants and method of producing the same |
| MY107937A (en) | 1990-02-13 | 1996-06-29 | Takeda Chemical Industries Ltd | Prolonged release microcapsules. |
| US6350730B1 (en) | 1994-08-17 | 2002-02-26 | The Rockefeller University | OB polypeptides and modified forms as modulators of body weight |
| US6429290B1 (en) | 1994-08-17 | 2002-08-06 | The Rockefeller University | OB polypeptides, modified forms and derivatives |
| US6001968A (en) | 1994-08-17 | 1999-12-14 | The Rockefeller University | OB polypeptides, modified forms and compositions |
| US6309853B1 (en) | 1994-08-17 | 2001-10-30 | The Rockfeller University | Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof |
| US5827734A (en) | 1995-01-20 | 1998-10-27 | University Of Washington | Materials and methods for determining ob protein in a biological sample |
| US5552522A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552524A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5552523A (en) | 1995-01-31 | 1996-09-03 | Eli Lilly And Company | Anti-obesity proteins |
| US5532336A (en) | 1995-01-31 | 1996-07-02 | Eli Lilly And Company | Anti-obesity proteins |
| US5521283A (en) | 1995-01-31 | 1996-05-28 | Eli Lilly And Company | Anti-obesity proteins |
| WO1996040912A1 (en) | 1995-06-07 | 1996-12-19 | Amgen Inc. | Ob protein compositions and method |
| IL122718A0 (en) | 1995-06-30 | 1998-08-16 | Lilly Co Eli | Methods for treating diabetes |
| EP0865294B1 (en) | 1995-08-17 | 2004-02-18 | Amgen Inc. | Methods of reducing or maintaining reduced levels of blood lipids using ob protein compositions |
| US20030040467A1 (en) | 1998-06-15 | 2003-02-27 | Mary Ann Pelleymounter | Ig/ob fusions and uses thereof. |
| ES2217327T3 (es) | 1995-11-22 | 2004-11-01 | Amgen Inc., | Proteina ob para aumentar la masa de tejido magro. |
| US6936439B2 (en) | 1995-11-22 | 2005-08-30 | Amgen Inc. | OB fusion protein compositions and methods |
| WO1997038014A1 (en) | 1996-04-04 | 1997-10-16 | Amgen Inc. | Fibulin pharmaceutical compositions and related methods |
| CA2258504A1 (en) * | 1996-06-20 | 1997-12-24 | Merck & Co., Inc. | Gene therapy for obesity |
| JP2001501177A (ja) | 1996-08-30 | 2001-01-30 | アムジエン・インコーポレーテツド | Ｏｂタンパク質受容体をアップレギュレートすることによりｏｂタンパク質に対する個体の感受性を増加させる方法 |
| BR9711513A (pt) | 1996-09-20 | 1999-08-24 | Hoechst Ag | Uso de antagonistas de leptina para o tratamento de resistencia a insulina em diabete do tipo ii |
| EP0839525B1 (en) | 1996-10-31 | 2004-08-04 | Takeda Chemical Industries, Ltd. | Sustained-release preparation |
| EA004790B1 (ru) | 1996-12-20 | 2004-08-26 | Амген Инк. | Композиции на основе слитого белка ов и способы их применения |
| ATE223229T1 (de) | 1997-04-17 | 2002-09-15 | Amgen Inc | Zusammensetzungen aus konjugaten des stabilen, aktiven, menschlichen ob proteins mit der fc kette von immunoglobulinen und damit zusammenhängende verfahren |
| TR199902980T2 (xx) | 1997-06-06 | 2000-05-22 | Smithkline Beecham P.L.C. | Diabetin tedavisi i�in leptin antagonistlerinin kullan�m�. |
| US7052678B2 (en) | 1997-09-15 | 2006-05-30 | Massachusetts Institute Of Technology | Particles for inhalation having sustained release properties |
| US6541033B1 (en) | 1998-06-30 | 2003-04-01 | Amgen Inc. | Thermosensitive biodegradable hydrogels for sustained delivery of leptin |
| PT1107793E (pt) | 1998-08-10 | 2005-02-28 | Amgen Inc | Conjugados de dextrano-leptina, composicoes farmaceuticas e processos relacionados |
| AU6396999A (en) | 1998-10-02 | 2000-04-26 | Amgen, Inc. | Method to determine a predisposition to leptin treatment |
| US6420339B1 (en) | 1998-10-14 | 2002-07-16 | Amgen Inc. | Site-directed dual pegylation of proteins for improved bioactivity and biocompatibility |
| CA2359840C (en) | 1999-02-12 | 2012-10-23 | Amgen Inc. | Glycosylated leptin compositions and related methods |
| PL214862B1 (pl) | 2001-10-22 | 2013-09-30 | Amgen | Sposób in vitro do okreslania predyspozycji pacjenta ludzkiego z lipoatrofia do reagowania na leczenie bialkiem leptyny, kompozycje farmaceutyczne do zastosowania do leczenia lipoatrofii i kompozycje farmaceutyczne zawierajace bialko leptyny |
| WO2004039832A2 (en) | 2002-10-31 | 2004-05-13 | Albany Medical College | Leptin-related peptides |
| JP4585186B2 (ja) * | 2003-07-31 | 2010-11-24 | 杏林製薬株式会社 | 肥満、糖尿病及び脂質代謝異常の新規な予防又は治療剤 |
| JP2009541423A (ja) * | 2006-06-23 | 2009-11-26 | ラボラトリオス・デル・ドクトル・エステベ・ソシエダッド・アノニマ | コリンエステラーゼ阻害剤と５‐ｈｔ６レセプター親和性の化合物との組合せ |
| US20110230551A1 (en) * | 2008-09-15 | 2011-09-22 | Leslie Gunatilaka | Withaferin a analogs and uses thereof |
| WO2010053655A2 (en) * | 2008-11-07 | 2010-05-14 | University Of Kansas | Therapeutic methods with withaferin a and analogs |
| US8598339B2 (en) * | 2011-02-01 | 2013-12-03 | University Of Kansas | Withanolide isolated from Physalis longifolia and analogs and methods of use thereof |
-
2014
- 2014-11-25 TR TR2019/01299T patent/TR201901299T4/tr unknown
- 2014-11-25 RS RS20190124A patent/RS58422B1/sr unknown
- 2014-11-25 ES ES14816018T patent/ES2709976T3/es active Active
- 2014-11-25 LT LTEP14816018.7T patent/LT3074033T/lt unknown
- 2014-11-25 HR HRP20190219TT patent/HRP20190219T1/hr unknown
- 2014-11-25 SM SM20190064T patent/SMT201900064T1/it unknown
- 2014-11-25 JP JP2016554826A patent/JP6672157B2/ja active Active
- 2014-11-25 AU AU2014354831A patent/AU2014354831B2/en not_active Ceased
- 2014-11-25 PL PL14816018T patent/PL3074033T3/pl unknown
- 2014-11-25 HU HUE14816018A patent/HUE042196T2/hu unknown
- 2014-11-25 US US15/039,743 patent/US20160375039A1/en not_active Abandoned
- 2014-11-25 PT PT14816018T patent/PT3074033T/pt unknown
- 2014-11-25 EP EP14816018.7A patent/EP3074033B1/en active Active
- 2014-11-25 SI SI201431046T patent/SI3074033T1/sl unknown
- 2014-11-25 WO PCT/US2014/067393 patent/WO2015081093A1/en not_active Ceased
- 2014-11-25 CA CA2931826A patent/CA2931826C/en active Active
- 2014-11-25 DK DK14816018.7T patent/DK3074033T3/en active
-
2018
- 2018-01-23 AU AU2018200517A patent/AU2018200517B2/en not_active Ceased
-
2019
- 2019-02-05 CY CY20191100155T patent/CY1122551T1/el unknown
- 2019-12-16 JP JP2019226600A patent/JP2020059744A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| HUE042196T2 (hu) | 2019-06-28 |
| JP6672157B2 (ja) | 2020-03-25 |
| EP3074033B1 (en) | 2018-11-07 |
| RS58422B1 (sr) | 2019-04-30 |
| AU2018200517A1 (en) | 2018-02-15 |
| ES2709976T3 (es) | 2019-04-22 |
| SI3074033T1 (sl) | 2019-03-29 |
| US20160375039A1 (en) | 2016-12-29 |
| LT3074033T (lt) | 2019-02-25 |
| DK3074033T3 (en) | 2019-02-11 |
| WO2015081093A1 (en) | 2015-06-04 |
| AU2014354831B2 (en) | 2017-10-26 |
| CA2931826A1 (en) | 2015-06-04 |
| AU2014354831A1 (en) | 2016-06-09 |
| EP3074033A1 (en) | 2016-10-05 |
| PL3074033T3 (pl) | 2019-08-30 |
| JP2016537431A (ja) | 2016-12-01 |
| SMT201900064T1 (it) | 2019-02-28 |
| JP2020059744A (ja) | 2020-04-16 |
| HRP20190219T1 (hr) | 2019-03-22 |
| TR201901299T4 (tr) | 2019-02-21 |
| AU2018200517B2 (en) | 2019-12-19 |
| CA2931826C (en) | 2021-11-16 |
| PT3074033T (pt) | 2019-02-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122551T1 (el) | Ενωσεις για τη θεραπεια της παχυσαρκιας και μεθοδοι χρησης αυτων | |
| CY1125290T1 (el) | Εφαρμογη r-κεταμινης και αλατος αυτης ως φαρμακα | |
| CY1124000T1 (el) | Υποκατεστημενες 5-φθορο-1η-πυραζολοπυριδινες σε κρυσταλλικη μορφη | |
| CY1123388T1 (el) | Υποκατεστημενου νικοτινιμιδιου αναστολεις της βτκ και παρασκευη αυτων και χρηση στη θεραπεια καρκινου, φλεγμονης και αυτοανοσης ασθενειας | |
| CY1120334T1 (el) | Υποκατεστημενης 3-αλλογονοαλυλαμινης αναστολεις ssao και χρησεις αυτων | |
| CY1123626T1 (el) | Ετεροκυκλικοι αναστολεις πρωτεϊνικης κινασης | |
| CY1121763T1 (el) | Παραγωγα διπυραζολιου ως αναστολεις jak | |
| CY1121549T1 (el) | Ενωσεις 1-αρυλκαρβονυλ-4-oξυ-πιπεριδινης χρησιμες για την αγωγη νευροεκφυλιστικων παθησεων | |
| CY1120104T1 (el) | Αναστολεις της syk | |
| CY1119487T1 (el) | Αναστολεις κιναζολινης των ενεργοποιητικων μεταλλαγμενων μορφων του υποδοχεα του επιδερμικου αυξητικου παραγοντα | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| CY1120031T1 (el) | Αποπτωτικοι υποκινητες ν-ακυλοσουλφοναμιδης | |
| EA202090860A1 (ru) | Аналоги тиадиазола и способы лечения состояний, связанных с дефицитом smn | |
| EA201390766A1 (ru) | БЕНЗОКСАЗЕПИНЫ КАК ИНГИБИТОРЫ PI3K/mTOR И СПОСОБЫ ИХ ИСПОЛЬЗОВАНИЯ И ПОЛУЧЕНИЯ | |
| CY1117559T1 (el) | Ενωση ινδολιου και φαρμακευτικη χρηση αυτου | |
| EA201291300A1 (ru) | Производные нафт-2-илуксусной кислоты для лечения спида | |
| EA201500300A1 (ru) | Способы применения с-мет-модуляторов | |
| CY1119433T1 (el) | Αμινο-υποκατεστημενες ιμιδαζοπυριδαζινες | |
| DOP2015000308A (es) | Inhibidores de bromodominios | |
| DOP2015000240A (es) | 3- pirimidin- 4- il- oxazolidin- 2- onas como inhibidores de idh mutante | |
| EA201391395A1 (ru) | Терапевтические соединения | |
| EA201591296A1 (ru) | Фталазиноны и изохинолиноны в качестве ингибиторов rock | |
| EA201300862A1 (ru) | Ингибирование il17 и ifn-гамма для лечения аутоиммунного воспаления | |
| EA201391644A1 (ru) | Частично насыщенные трициклические соединения и способы их получения и применения | |
| CY1118947T1 (el) | Ασυμμετρες ουριες και ιατρικες χρησεις αυτων |